🔎 Trials Near Me

Home › Acute Biphenotypic Leukemia › Missouri › St. Louis

Acute Biphenotypic Leukemia clinical trials in St. Louis, MO

4 studies for Acute Biphenotypic Leukemia are looking for participants at sites in and around St. Louis (within about 30 miles). Open a study to see who can join and how to contact the study team.

Recruiting for a study here? Feature it at the top of this page — $99 for 30 days →

Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia

RecruitingPhase 2
  • Washington University School of Medicine, St Louis
  • Mercy Hospital Saint Louis, St Louis
365 Days · All sexes · Updated Sep 25, 2026 · NCT06317662

A Study of Revumenib in R/R Leukemias Including Those With an MLL/KMT2A Gene Rearrangement or NPM1 Mutation

RecruitingPhase 1/2
  • Washington University in St. Louis School of Medicine, St Louis
30 Days · All sexes · Updated Sep 16, 2026 · NCT04065399

Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy

RecruitingPhase 3
  • Cardinal Glennon Children's Medical Center, St Louis
  • Washington University School of Medicine, St Louis
  • Mercy Hospital Saint Louis, St Louis
365 Days – 25 Years · All sexes · Updated Aug 25, 2026 · NCT03959085

The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study

RecruitingPhase 1/2
  • Cardinal Glennon Children's Medical Center, St Louis
  • Washington University School of Medicine, St Louis
  • Mercy Hospital Saint Louis, St Louis
Up to age 22 · All sexes · Updated Aug 25, 2026 · NCT04726241

Acute Biphenotypic Leukemia trials in other cities

Other studies in St. Louis

From ClinicalTrials.gov, data retrieved Oct 6, 2026. Each study sets its own eligibility; the study team decides who can join.